This study is an Investigator initiated, randomized, multicenter, double-blind, placebo-control study. The aim of this study is to evaluate the safety and efficiency of Sirolimus for primaty antiphospholipid syndrome patients at week 24 and week 48.
Understand and sign the informed consent form
Male or Female
aged 18-70 at the time of screening visit
Met 2006 Sapporo classification criteria of APS or 2023 ACR/EULAR classification criteria of APS
history of serious adverse events or contraindication to Sirolimus
Catastrophic APS within 90 days
Acute thrombosis within 30 days
≥4/11 American College of Rheumatology Classification Criteria for SLE or other systemic autoimmune diseases